Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter Phase III Study to Assess the Efficacy of Panobinostat Maintenance Therapy vs. Standard of Care Following Allogeneic Stem Cell Transplantation in Patients With High-risk AML or MDS (ETAL-4 / HOVON-145)

NCT04326764 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT04326764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04326764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter Phase III Study to Assess the Efficacy of Panobinostat Maintenance Therapy vs. Standard of Care Following Allogeneic Stem Cell Transplantation in Patients With High-risk AML or MDS (ETAL-4 / HOVON-145)
Lead sponsor
Goethe University
Phase
Phase 3
Overall status
Terminated
Start date
July 24, 2018
Completion date
February 13, 2023
Enrollment
52 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml), myelodysplastic syndromes (mds)